BioWorld1 小时
Novo’s injectable hemophilia treatment approved by FDA
With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...
The American Journal of Managed Care2 小时
First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA
The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...
Managed Healthcare Executive3 小时
Alhemo Once-Daily Treatment for Hemophilia A, B with Inhibitors FDA Approved
The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...
2seventy bio: All In On Abecma Multiple Myeloma Treatment
Explore the investment prospects of 2seventy Bio, a spin-off from bluebird bio, in the competitive field of cell therapies ...
FiercePharma9 小时
Novo Nordisk wins hard-fought FDA approval for once-daily hemophilia med Alhemo
Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...
Medscape10 小时
Hemophilia A: Bleeds Plummet After Experimental Gene Therapy
Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer ...
ENDPOINTS NEWS11 小时
No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US
FDA approves Novo Nordisk's Alhemo for hemophilia A and B with inhibitors. Once-daily shot reduces bleeding episodes in ...